{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:40:20Z","timestamp":1791186020782,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1136\/ard.2010.141150","type":"journal-article","created":{"date-parts":[[2011,2,21]],"date-time":"2011-02-21T09:33:24Z","timestamp":1298280804000},"page":"i119-i122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"special_numbering":"S1","title":["Targeting sclerostin as potential treatment of osteoporosis"],"prefix":"10.1016","volume":"70","author":[{"given":"Socrates E","family":"Papapoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2010.141150_bib1","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.berh.2005.07.004","article-title":"Determinants of skeletal fragility","volume":"19","author":"Bouxsein","year":"2005","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1136\/ard.2010.141150_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clinthera.2004.12.020","article-title":"The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management","volume":"27","author":"Felsenberg","year":"2005","journal-title":"Clin Ther"},{"key":"10.1136\/ard.2010.141150_bib3","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1056\/NEJMra053077","article-title":"Bone quality\u2013the material and structural basis of bone strength and fragility","volume":"354","author":"Seeman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2010.141150_bib4","first-page":"115","article-title":"Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis","volume":"21","author":"Manolagas","year":"2000","journal-title":"Endocr Rev"},{"key":"10.1136\/ard.2010.141150_bib5","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1359\/JBMR.040710","article-title":"Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients","volume":"19","author":"Recker","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1136\/ard.2010.141150_bib6","doi-asserted-by":"crossref","unstructured":"Parfitt AM,. Skeletal heterogeneity and the purpose of bone remodeling; implications for the understanding of osteoporosis. In: Marcus R, Feldman D, Kelsey J, eds. Osteoporosis. San Diego, CA: Academic Press, 2001;433\u201347.","DOI":"10.1016\/B978-012470862-4\/50016-7"},{"key":"10.1136\/ard.2010.141150_bib7","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.beem.2008.07.001","article-title":"Bisphosphonates: how do they work?","volume":"22","author":"Papapoulos","year":"2008","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1136\/ard.2010.141150_bib8","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2010.141150_bib9","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1359\/jbmr.091035","article-title":"Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density","volume":"25","author":"Bone","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1136\/ard.2010.141150_bib10","doi-asserted-by":"crossref","first-page":"S217","DOI":"10.1016\/j.bone.2010.04.517","article-title":"Phase 3 Fracture trial of odanacatib for osteoporosis- study design","volume":"47","author":"McClung","year":"2010","journal-title":"Bone"},{"key":"10.1136\/ard.2010.141150_bib11","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.bone.2006.09.008","article-title":"Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure","volume":"40","author":"Compston","year":"2007","journal-title":"Bone"},{"key":"10.1136\/ard.2010.141150_bib12","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1586\/eem.10.48","article-title":"Targeting the Wnt signaling pathway for the development of novel therapies for osteoporosis","volume":"5","author":"Yavropoulou","year":"2010","journal-title":"Expert Rev Endocrinol Metab"},{"key":"10.1136\/ard.2010.141150_bib13","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1084\/jem.20031454","article-title":"Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist","volume":"199","author":"van Bezooijen","year":"2004","journal-title":"J Exp Med"},{"key":"10.1136\/ard.2010.141150_bib14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.cytogfr.2005.02.005","article-title":"SOST\/sclerostin, an osteocyte-derived negative regulator of bone formation","volume":"16","author":"van Bezooijen","year":"2005","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1136\/ard.2010.141150_bib15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00223-010-9372-1","article-title":"Sclerostin: current knowledge and future perspectives","volume":"87","author":"Moester","year":"2010","journal-title":"Calcif Tissue Int"},{"key":"10.1136\/ard.2010.141150_bib16","doi-asserted-by":"crossref","first-page":"E1526","DOI":"10.1002\/humu.21274","article-title":"First missense mutation in the SOST gene causing sclerosteosis by loss of sclerostin function","volume":"31","author":"Piters","year":"2010","journal-title":"Hum Mutat"},{"key":"10.1136\/ard.2010.141150_bib17","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.bone.2005.03.018","article-title":"SOST is a target gene for PTH in bone","volume":"37","author":"Keller","year":"2005","journal-title":"Bone"},{"key":"10.1136\/ard.2010.141150_bib18","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1074\/jbc.M705092200","article-title":"Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost\/sclerostin","volume":"283","author":"Robling","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1136\/ard.2010.141150_bib19","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1359\/jbmr.080216","article-title":"Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength","volume":"23","author":"Li","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1136\/ard.2010.141150_bib20","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1093\/emboj\/cdg599","article-title":"Osteocyte control of bone formation via sclerostin, a novel BMP antagonist","volume":"22","author":"Winkler","year":"2003","journal-title":"EMBO J"},{"key":"10.1136\/ard.2010.141150_bib21","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1359\/jbmr.081206","article-title":"Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis","volume":"24","author":"Li","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1136\/ard.2010.141150_bib22","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/jbmr.14","article-title":"Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength","volume":"25","author":"Ominsky","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1136\/ard.2010.141150_bib23","unstructured":"Ominsky M, Samadfam R, Jolette J, et al. Sclerostin monoclonal antibody stimulates bone formation and improves the strength and density of the fracture callus and lumbar spine in a primate fibular osteotomy model. Presented at the 31st Annual Meeting of ASBMR, 11\u201315 September 2009, Denver, Colorado, USA."},{"key":"10.1136\/ard.2010.141150_bib24","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1359\/jbmr.090403","article-title":"A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis","volume":"24","author":"Eddleston","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1136\/ard.2010.141150_bib25","article-title":"Single-dose, placebo-controlled, randomised study of AMG 785, a sclerostin monoclonal antibody","author":"Padhi","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1136\/ard.2010.141150_bib26","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1210\/jc.2005-1235","article-title":"Bone mineral density in sclerosteosis; affected individuals and gene carriers","volume":"90","author":"Gardner","year":"2005","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724497537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724497537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2010.141150","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T14:38:37Z","timestamp":1737556717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724497537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":26,"alternative-id":["S0003496724497537"],"URL":"https:\/\/doi.org\/10.1136\/ard.2010.141150","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting sclerostin as potential treatment of osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2010.141150","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}